Nucleate Podcast

Nucleate
Nucleate Podcast

Nucleate is the new voice for next generation biotech leaders.

  1. 8 DE DEZ.

    The Vagina Business | Marina Gerner

    We are very excited to have Dr Marina Gerner joining us on the Nucleate Pocast to discuss her book called The Vagina Business. The Vagina Business has already been getting attention with grants from the Alfred P. Sloan Foundation and The Society of Authors. Kirkus Reviews has praised the book as "energetic, thoroughly engaging reading" and emphasized its potential to improve women's health outcomes worldwide. It has also been recommended as a must-read business book by the Financial Times. As a journalist, Marina has written about books and arts, as well as finance and tech for over a decade. Her range of expertise has led to Marina being called "a Renaissance woman of the modern age." ​Marina has won several awards and written for The Economist, Jewish Chronicle, Guardian, Financial Times, Wired, the Times Literary Supplement, The Times, and the Wall Street Journal. She has been a contributing editor at The Sunday Times Raconteur, the i newspaper and MoneyWeek. Before that she was a Staff Writer at Money Observer, where she wrote a column called “Marina’s Imaginary Millions.”​ She is an Adjunct Professor of Commerce & Culture at the NYU Stern School of Business (on their London campus) and she has a PhD from the London School of Economics, which was funded by merit-based scholarships.​

    41min

  2. 19 DE NOV.

    The Art of the Pitch: Storytelling in Film and Biotech | Michael Langer, T.Rx Capital

    Michael Langer has had a diverse and fascinating career, with experience spanning startups, venture capital, biotech, filmmaking, and philanthropy. He was inspired from a young age by his father's work in the Langer Lab and early exposure to the startup world. Langer's background includes formative experiences like an impactful internship at Living Proof and taking time off from college to backpack internationally, which he credits with shaping his entrepreneurial mindset. Langer reflects on lessons learned from his time at Pear Therapeutics, particularly around navigating business models and regulatory risks in the digital health space. This experience has informed his approach to investing in tech bio companies at his new fund, T.Rx Capital. Throughout the conversation, Langer emphasizes the critical role of storytelling in entrepreneurship and investing, providing insights on how founders can effectively communicate their vision.

    37min

  3. 3 DE NOV.

    Unlocking the power of the gut microbiome with AI | Leo Grady, Jona

    In this episode, Anastasia Janas interviews Leo Grady, founder and CEO of Jona. With over 20 years in AI and healthcare, Leo has made a profound impact on the field, including leading the development of the first FDA-approved AI system in pathology at Paige.AI. Together, they dive into the journey that led him to create Jona, a company focused on using AI to analyze the gut microbiome for personalized health insights. Leo shares his thoughts on AI's role in healthcare today, from emerging trends to its transformative potential in improving patient outcomes. Drawing on his own experience building Jona, he offers practical advice for those looking to enter healthcare AI, touching on the unique challenges and opportunities in biotech. With over 100 peer-reviewed papers and 300 patents to his name, Leo’s contributions to AI-driven healthcare are significant. This episode is packed with insights and inspiration for anyone interested in the future of healthcare innovation!

    45min

  4. 20 DE OUT.

    Biotech journalism & scaling new heights for a good cause | Luke Timmerman, Timmerman Report

    In this episode, Sam Kessel and Anastasia Janas interview Luke Timmerman, an award-winning biotech journalist and founder of the Timmerman Report, as well as host of The Long Run Podcast. They explore Luke's non-traditional background, his curiosity, and his openness to learning, which shaped his journey to becoming a prominent figure in the biotech space. Luke shares insights into his career, discussing his book Hood, the founding of the Timmerman Report, and his podcast. He also offers his perspective on the key qualities of biotech founders and VCs, the importance of diversity, and how to unlock individuals' full potential. Additionally, Luke discusses his passion for mountaineering and how he combined it with his work, creating the Timmerman Traverse, a series of fundraising expeditions that have raised over $12M for causes such as cancer, poverty, and sickle cell disease.

    1h1min

  5. 29 DE SET.

    Patient-Centered Innovation | Irene Blat, Servier

    In this episode, Sam Kessel speaks with Irene Blat, Senior Director for Search and Evaluation at Servier. Dr Blat discusses her lifelong fascination with science and inspiration to take her Oncology studies to industry to develop new therapies for patients. She discussed the intersection of science and business in Search and Evaluation identifying promising technologies. She talks about the key aspects of early-stage biotechs she evaluates for partnerships with Servier and the emphasis on the patient experience at every stage of the R&D process. Dr Blat also touches how the biotech industry can improve in diversity and how she has integrated her work and family life together.

    41min

  6. 28 DE AGO.

    Fostering Innovation in Biotech | Fiona Mack Bayer Co.Lab

    In this episode, Sam Kessel and Vianca Williams speak with Fiona Mack, the head of Bayer's Co.Lab in Cambridge. Dr Mack discusses her career path from Cornell and the University of Pennsylvania to Bayer, highlighting her transition from academia to industry. She emphasizes the importance of mentorship and risk-taking in her journey. Dr Mack describes Bayer Co.Lab's mission to support early-stage biotechs with lab space, mentorship, and resources, aiming to accelerate their growth. She notes the global expansion of Bayer Co.Lab to Cambridge, Berlin, Shanghai, and Kobe, and the focus on translational medicine and external innovation. Dr Mack also touches on trends in biotech, including AI, women's health, and the need for diversity in the workforce.

    45min

  7. 12 DE AGO.

    Engineering Dendritic Cells to Treat Cancer (Part 2) | Guardian Bio

    In this episode of the Nucleate Podcast, we are joined by Ananya Zutshi and Ricky Barrett, founders of Guardian Bio, a Boston-based biotech company (and Nucleate Alumni). Their platform focuses on engineering dendritic cells to target solid tumors. We delve into the ups and downs of their entrepreneurial journey, the unique dynamic between co-founders, and their advice for communicating complex science topics.

    37min

  8. 12 DE AGO.

    Engineering Dendritic Cells to Treat Cancer (Part 1) | Guardian Bio

    In this episode of the Nucleate Podcast, we are joined by Ananya Zutshi and Ricky Barrett, founders of Guardian Bio, a Boston-based biotech company (and Nucleate Alumni). Their platform focuses on engineering dendritic cells to target solid tumors. We delve into the ups and downs of their entrepreneurial journey, the unique dynamic between co-founders, and their advice for communicating complex science topics.

    40min
Ver tudo (16)

Classificações e avaliações

5
de 5
2 avaliações

Sobre

Nucleate is the new voice for next generation biotech leaders.

Informações

  • Criado por
    Nucleate
  • Anos de atividade
    2023 - 2024
  • Episódios
    16
  • Classificação
    Livre
  • Copyright
    © 2024 Nucleate Podcast
  • Site do podcast
    Nucleate Podcast

Você também pode gostar de

Para ouvir episódios explícitos, inicie sessão.

Fique por dentro deste podcast

Inicie sessão ou crie uma conta para seguir podcasts, salvar episódios e receber as atualizações mais recentes.
Selecionar um país ou região

África, Oriente Médio e Índia

Ásia‑Pacífico

Europa

América Latina e Caribe

Estados Unidos e Canadá